<unk>  (formerly velcalcetide, trade name Parsabiv) is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis. It is administered intravenously at the end of each dialysis session.<unk>  functions by binding to and activating the calcium-sensing receptor in the parathyroid gland. Parsabiv is currently owned by Amgen and Ono Pharmaceuticals in Japan.
Etelcalcetide
Efmoroctocog alfa
Vonicog alfa
Drotrecogin alfa
Moroctocog alfa
Difelikefalin
Glucagon 
Glucagon